1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Doxorubicin Hydrochloride Powder for Injection

Trade Name: Adriamycin, Adriblastina
Synonyms: Doxorubicin RDF Injection
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Red-orange powder
Signal Word: DANGER

Statement of Hazard: May damage fertility or the unborn child.
May cause cancer.
May cause genetic defects.

Additional Hazard Information:

Short Term: Effects of ingestion are not known. Avoid swallowing this material. Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes, the developing fetus.

Known Clinical Effects: Bone marrow suppression is the most serious adverse effect seen during clinical use.

EU Indication of danger:
- Toxic to reproduction, Category 2
- Carcinogenic: Category 2
- Mutagenic: Category 2

EU Hazard Symbols:

EU Risk Phrases:
- R45 - May cause cancer.
- R46 - May cause heritable genetic damage.
- R60 - May impair fertility.
- R61 - May cause harm to the unborn child.
2. HAZARDS IDENTIFICATION


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin Hydrochloride</td>
<td>25316-40-9</td>
<td>246-818-3</td>
<td>Repr.Cat.2;R60-61 Carc.Cat.2;R45 Mut.Cat.2;R46</td>
<td>16.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylparaben</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
MATERIAL SAFETY DATA SHEET

Material Name: Doxorubicin Hydrochloride Powder for Injection
Revision date: 16-Mar-2011

Fire / Explosion Hazards:
Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Doxorubicin Hydrochloride
Pfizer OEL TWA-8 Hr: 0.5 µg/m³


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Lyophilized powder
Molecular Formula: Mixture
Color: Red-orange
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Doxorubicin Hydrochloride

Mouse Oral LD50 698 mg/kg
Mouse Para-periosteal LD50 1.2 mg/kg
Rat Intravenous LD50 12.5 mg/kg
Rat Intraperitoneal LD50 16 mg/kg

Lactose
Rat Oral LD50 > 10 g/kg

Methylparaben

Mouse Oral LD50 > 8000 mg/kg
Rat Oral LD50 2280 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Doxorubicin Hydrochloride

Reproductive & Fertility-Females Rat Intraperitoneal 0.05 mg/kg/day LOAEL Fertility
Reproductive & Fertility-Males Rat Intraperitoneal 0.1 mg/kg/day LOAEL Fertility
Embryo / Fetal Development Rat Intraperitoneal 0.8 mg/kg/day LOAEL Teratogenic, Embryotoxicity
Embryo / Fetal Development Rabbit Intraperitoneal 0.4 mg/kg/day LOAEL Embryotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Doxorubicin Hydrochloride

Bacterial Mutagenicity (Ames) Salmonella, E. coli Positive
In Vivo Micronucleus Mouse Positive
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Positive
In Vitro Sister Chromatid Exchange Human Lymphocytes Positive
Dominant Lethal Assay Mouse Positive
11. TOXICOLOGICAL INFORMATION

Carcinogen Status: See below

Doxorubicin Hydrochloride
IARC: 2A
NTP: Listed
OSHA: Present

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to reproduction, Category 2
Carcinogenic: Category 2
Mutagenic: Category 2

EU Risk Phrases:
R45 - May cause cancer.
R46 - May cause heritable genetic damage.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

EU Safety Phrases:
S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.
15. REGULATORY INFORMATION

OSHA Label:
DANGER
May damage fertility or the unborn child.
May cause cancer.
May cause genetic defects.

Canada - WHMIS: Classifications
WHMIS hazard class:
D2a very toxic materials

Methylparaben
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
EU EINECS/ELINCS List 202-785-7

Lactose
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
EU EINECS/ELINCS List 200-559-2

Doxorubicin Hydrochloride
California Proposition 65 Listed: Developmental Toxicity, Cancer, and Male Reproductive Toxicity
EU EINECS/ELINCS List 246-818-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R45 - May cause cancer.
R46 - May cause heritable genetic damage.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communications
                   Pfizer Global Environment, Health, and Safety Operations
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet